Company intelligence / Profile preview

Ingenza

Ownership: Private
Employees: ~40
Development stage: Commercial

Overview

Ingenza provides advanced technology platforms that accelerate product development from drug discovery through pre-clinical evaluation toward first-in-human studies. The company has contributed to the development of a protein subunit vaccine for COVID–19 in partnership with Oxford University and CPI. It does not have its own clinical pipeline but supports client programs across multiple stages.

Therapeutic areas: Infectious Diseases
Modalities: Recombinant proteinTherapeutic proteinsSmall moleculeMicrobial therapyMammalian cell-based biologics
Industry: Drug Discovery Services

Partnerships

Oxford University (COVID–19 vaccine project)UK Centre for Process Innovation/CPI

Beyond the preview

Go deeper on Ingenza.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ingenza.

Explore the full profile